<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896298</url>
  </required_header>
  <id_info>
    <org_study_id>0502-294</org_study_id>
    <nct_id>NCT00896298</nct_id>
  </id_info>
  <brief_title>Trial of Leptin Replacement Therapy in Patients With Lipodystrophy</brief_title>
  <official_title>Double-Blind, Placebo-Controlled Trial of Leptin Replacement Therapy in Patients With Lipodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lipodystrophies represent a therapeutic challenge with regards to insulin resistance,
      hypertriglyceridemia and fatty liver which often is coupled with significant adipose tissue
      loss. The purpose of the study is to examine the safety and efficacy of Leptin on subjects
      with lipodystrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanism by which leptin improves glucose and lipid control is not clear. We will
      examine the possible mechanisms of leptin action by studying the effects of leptin
      administration on food intake, insulin resistance, insulin secretory response, hepatic and
      intramuscular triglyceride stores in a large sample of patients with lipodystrophy.

      Hypothesis: Leptin replacement in patients with generalized and partial lipodystrophy and
      hypoleptinemia will be safe and efficacious in improving the metabolic abnormalities
      associated with insulin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Serum Triglycerides</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Serum Glucose</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hypoleptinemia</condition>
  <condition>Generalized Lipodystrophy</condition>
  <condition>Partial Lipodystrophy</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>1 Leptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator for 4 months, then for 8 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 4 months, then active comparator for 8 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leptin</intervention_name>
    <description>Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.</description>
    <arm_group_label>1 Leptin</arm_group_label>
    <other_name>Recombinant-methionyl Human Leptin.</other_name>
    <other_name>r-metHuLeptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill</description>
    <arm_group_label>2 Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 6 years

          -  Partial and generalized lipodystrophy

          -  Serum leptin levels less than the 7th percentile of normal values reported by the 3rd
             National Health and Nutrition Examination survey (less than 7.0 ng/mL in females and
             less than 3/0 ng/mL in males)

          -  Presence of at least one of the following metabolic abnormalities:

               1. Type 2 Diabetes Mellitus

               2. Fasting serum insulin &gt;20 uU/mL

               3. Fasting serum triglycerides &gt; 300 mg/dL

               4. Previous participation in leptin trial (Amgen 991265, GCRC 660) - for Part B of
                  the Study.

        Exclusion Criteria:

          -  Known liver disease due to causes other than non-alcoholic steatohepatitis.

          -  Hematocrit of less than 30%.

          -  Current alcohol or substance abuse.

          -  Use of anorexigenic drugs, anabolic steroids, GH and thiazolidinediones

          -  Active tuberculosis

          -  Psychiatric disorder impeding competence or compliance

          -  Malignancies

          -  HIV infection

          -  Subjects who have a known hypersensitivity to E. Coli derived proteins

          -  Other condition, which in the opinion of the clinical investigators would impede
             completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhimanyu Garg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2009</study_first_posted>
  <results_first_submitted>January 15, 2019</results_first_submitted>
  <results_first_submitted_qc>February 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Abhimanyu Garg</investigator_full_name>
    <investigator_title>Chairman, Division Nutrition and Metabolic Diseases, Professor Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Lipodystrophy</keyword>
  <keyword>Insulin secretory response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy, Congenital Generalized</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Leptin Therapy</title>
          <description>Randomized to Leptin Therapy for 4 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Randomized to Placebo for 4 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leptin Therapy</title>
          <description>Participants were randomized to receive Leptin .</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants were randomized to receive Placebo .</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="11.9"/>
                    <measurement group_id="B2" value="24.9" spread="13"/>
                    <measurement group_id="B3" value="26.1" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="17.5"/>
                    <measurement group_id="B2" value="57.7" spread="16.0"/>
                    <measurement group_id="B3" value="61.8" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting serum Triglycerides</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309.3" lower_limit="69.3" upper_limit="1096.7"/>
                    <measurement group_id="B2" value="443.8" lower_limit="104.7" upper_limit="3556.3"/>
                    <measurement group_id="B3" value="309.3" lower_limit="69.3" upper_limit="3556.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting serum Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.0" spread="74.2"/>
                    <measurement group_id="B2" value="184.0" spread="87.2"/>
                    <measurement group_id="B3" value="170.0" spread="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>% of haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="2.5"/>
                    <measurement group_id="B2" value="8.0" spread="2.5"/>
                    <measurement group_id="B3" value="8.0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fasting Serum Triglycerides</title>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leptin Therapy</title>
            <description>Randomized to Leptin Therapy for 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized to Placebo for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Serum Triglycerides</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" lower_limit="100" upper_limit="457"/>
                    <measurement group_id="O2" value="304" lower_limit="129" upper_limit="3875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2572</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HbA1c</title>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leptin Therapy</title>
            <description>Randomized to Leptin Therapy for 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized to Placebo for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c</title>
          <units>% of haemoglobin</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="5" upper_limit="12"/>
                    <measurement group_id="O2" value="7.6" lower_limit="5.1" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Serum Glucose</title>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leptin Therapy</title>
            <description>Randomized to Leptin Therapy for 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized to Placebo for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Serum Glucose</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" lower_limit="77" upper_limit="310"/>
                    <measurement group_id="O2" value="165" lower_limit="77" upper_limit="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight</title>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leptin Therapy</title>
            <description>Randomized to Leptin Therapy for 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized to Placebo for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="17.5"/>
                    <measurement group_id="O2" value="56.3" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0256</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Leptin Therapy</title>
          <description>Randomized to Leptin Therapy for 4 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Randomized to Placebo for 4 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Pneumonia twice. Went To ER and took oral antibiotics</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry Vision and Epigastric pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <description>Nausea and cramps</description>
                <counts group_id="E1" events="13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>viral illness, sinusitis, backache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Right Ankle Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Abhimanyu Garg</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-2895</phone>
      <email>abhimanyu.garg@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

